Home > News > Too Little Bang for the Buck in Drug Research?
December 27th, 2006
Too Little Bang for the Buck in Drug Research?
"Researchers are tackling increasingly complex diseases using new tools—such as genomics, proteomics and nanotechnology—that will take years to bear fruit," says PhRMA Senior Vice President Ken Johnson, adding that "more than 2,000 new medicines are in development, including 646 medicines for cancer, 146 for heart disease and stroke, 77 for AIDS, and 56 for diabetes."
Malvern specialist to explore use of Nanoparticle Tracking Analysis for characterizing extracellular vesicles at ISEV 2014 March 11th, 2014
Arrowhead to Present at Barclays Global Healthcare Conference March 11th, 2014
Production of Bioactive Material for Quick Treatment of Bone Damages March 10th, 2014
Production of New Type of Electrochemical Drug Sensors for Cardiovascular Diseases March 10th, 2014
Harris & Harris Group Notes D-Wave's Article in Phys.Org March 11th, 2014
Analysis of Electromagnetic Performance, Coupling of Couple Nanoholes March 10th, 2014
A bright future for optoelectronics: A diode made from a 2D material facilitates novel solar cells March 10th, 2014
Scientists build thinnest-possible LEDs to be stronger, more energy efficient March 10th, 2014
Harry Potter-style invisibility cloaks: A real possibility next Christmas? Forget socks and shaving foam, the big kids of tomorrow want an invisible cloak for Christmas December 19th, 2013
Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants December 12th, 2013
ZEISS Microscopes used to create images for Art Exhibit at Midway Airport: Art of Science: Images from the Institute for Genomic Biology October 25th, 2013
New potential for touch screens found at your fingertips September 17th, 2013